bm‑t betei­li­gungs­ma­nage­ment thü­rin­gen gmbh, manage­ment com­pany of the PET Pri­vate Equity Thü­rin­gen GmbH & Co. KG fund and VACT AG acquire a mino­rity stake in Greiz based com­pany AVISO GmbH. The pro­vi­ded capi­tal will be used for laun­ching AVISO’s new “CellCelector”product line.
Dr. Guido Boh­nen­kamp, Gene­ral mana­ger of bm‑t, sta­tes that “ the sus­tainable pro­duct deve­lo­p­ment, the close coope­ra­tion with uni­ver­si­ties and rese­arch insti­tu­tes as well as the pro­found pro­fes­sio­nal expe­ri­ence of the com­pany foun­der and for­mer sole share­hol­der Rein­hard Herr­mann were cru­cial ele­ments of our decis­ion to invest in AVISO”.
Accor­ding to Frank Han­ser, exe­cu­tive chair­man of the VACT AG, this decis­ion is “an uni­que pos­si­bi­lity to invest into a bene­fi­cial and highly inno­va­tive com­pany. This effi­ci­ently struc­tu­red busi­ness enables us simul­ta­neously to sup­port the deve­lo­p­ments for the coll­ec­tive goods, e.g. in rege­ne­ra­tive medicine.”
Within a few years, the AVSIO-Team suc­cee­ded in deve­lo­ping a world­wide uni­que tech­no­logy for cell bio­lo­gi­cal rese­arch. The Cell­Celec­tor and other sys­tems, that are still in the state of deve­lo­p­ment, sup­port the stu­dies in rege­ne­ra­tive medi­cine and in can­cer rese­arch. One of the first and important cus­to­mers is the US Ame­ri­can White Head Insti­tute who is curr­ently making world news with its achie­ve­ments in repro­gramma­ble soma­tic cells to stem cells.
“When rege­ne­ra­tive medi­cine has rea­ched a state in which skin, car­ti­lage or organs can be grown of human soma­tic cells and trans­plan­ted, then we are able to allay pain and to abort dise­a­ses. Con­se­quently, we can res­tore many people’s qua­lity of life. Within this large field of pro­s­pects AVISO aims to launch tech­no­lo­gies that per­mit rese­arch and indus­try to fas­ter achieve valuable results”, CEO Rein­hard Herr­mann says. At pre­sent, AVISO main­ta­ins rese­arch coope­ra­tion to many uni­ver­si­ties and insti­tu­tes. This close net­work enables AVISO to directly imple­ment cus­to­mer demands into the rese­arch and deve­lo­p­ment pro­cess and ulti­m­ately gain a per­ma­nent com­pe­ti­tive advantage.

About AVISO

AVISO is a com­pe­tent part­ner for the deve­lo­p­ment and pro­duc­tion of inno­va­tive sys­tems for labo­ra­tory auto­ma­tion. With the focus on niches with great growth poten­tial within the bio­tech­no­logy branch AVISO deve­lops its inno­va­tions in close coope­ra­tion with cus­to­mers and rese­arch insti­tu­tes in Europe, Asia and Nor­t­hern Ame­rica. Resul­ting from this part­ner­ship are pro­ducts with highly inter­na­tio­nal mar­ket accep­tance. In 2005, the AVISO has taken over the auto­ma­tion branch of the MWB Bio­tech AG and ther­eby increased its port­fo­lio of liquid hand­ling sys­tems. The com­pany ope­ra­tes on the mar­kets in Ger­many, UK, and France and in the US with an own ser­vice and sales struc­ture. Moreo­ver, the AVISO is a long-time expe­ri­en­ced part­ner in OEM busi­ness. Tog­e­ther with its cus­to­mers they deve­lop and pro­duce assem­blies and instru­ments which are in use all over the world.
www.aviso-gmbh.de

About VACT

VACT has deve­lo­ped an equity and mez­za­nine pro­duct “Fas­zi­na­tion Mit­tel­stand” that focu­ses on small and medium sized busi­nesses in Ger­many. The com­pany has inves­ted in indus­tries such as secu­rity and com­mu­ni­ca­ti­ons, ser­vices, medi­cal engi­nee­ring and energy and envi­ron­men­tal technology.

Contact

AVISO GmbH
Verena Büch
Assistant to Management
Tal­strasse 44
D‑07545 Gera
T: +49 365 55 191–42
F: +49 365 55 191–43
vb@aviso-trade.de
www.aviso-gmbh.de
VACT AG
Vorstand
Frank K. M. Hanser
Erdin­ger Straße 84
D‑85356 Freising
T: +49 8161 23471–0
F: +49 8161 23471–9
fh@vact-ag.de